Agilent system removes 99 per cent of proteins
removal system for proteomics research, that removes up to 99 per
cent of the six most common proteins from human blood serum.
This high-capacity version of its human protein Multiple Affinity Removal System will allow researchers to detect and identify low-abundance proteins that may serve as markers for a wide range of diseases. Additionally the system can purify approximately twice the volume of serum per sample compared with other protein removal systems.
Biomarkers can be used for applications including early cancer detection, quick detection of heart attack and early assessment of drug toxicity or efficacy. Proteins that are representative of disease processes are typically present in small amounts in human serum and can indicate a disease or a potential response to therapy.
By doubling the throughput of protein removal, the new Agilent High-Capacity Multiple Affinity Removal System makes it easier for researchers to eliminate high-abundance proteins from larger sample volumes.
The new high-capacity affinity removal system is available in both HPLC column and spin cartridge formats, facilitating protein removal through liquid chromatography (LC) or centrifugation techniques.
The new high-capacity products can be reused for more than 200 runs and are compatible with most standard LC instruments and bench top centrifuges.
"This high-capacity system will help to improve the speed, efficiency and productivity of human biomarker research," said Mary Pat Knauss, bioreagents business manager at Agilent. "The new system promises to enhance scientists' ability to delve into the human proteome and advance the progress of proteomic research."
The High-Capacity Multiple Affinity Removal System is available now. Additional information is available at Agilent's website
